Compare
Biogen vs AbbVie
MonkScore ranges and fundamentals, side by side
Key facts
Biogen and AbbVie: key facts
- In fiscal 2025, Biogen Inc. reported revenue of $9.8B and net income of $1.3B.
- In fiscal 2025, AbbVie Inc. reported revenue of $61.2B and net income of $4.2B.
- Biogen Inc.'s revenue fell 2.8% a year from fiscal 2021 to fiscal 2025.
- AbbVie Inc.'s revenue grew 2.1% a year from fiscal 2021 to fiscal 2025.
- Biogen Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- AbbVie Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Biogen Inc. reported revenue of $10.3B and net income of $348.0M.
- In the twelve months to 30 June 2026, AbbVie Inc. reported revenue of $64.4B and net income of $6.3B.
Side by side
Biogen and AbbVie, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Biogen Inc.NASDAQ:BIIB | AbbVie Inc.NYSE:ABBV |
|---|---|---|
| MonkScore | ||
| MonkScore range | 50–60as of October 2026 | 90–100as of October 2026 |
| Sector rank | 352 of 628 in Healthcare | 64 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $9.8BFY 2025 | $61.2BFY 2025 |
| Net income | $1.3BFY 2025 | $4.2BFY 2025 |
| Free cash flow | $2.1BFY 2025 | $17.8BFY 2025 |
| Operating cash flow | $2.2BFY 2025 | $19.0BFY 2025 |
| Total debt | $6.9BFY 2025 | $69.1BFY 2025 |
| Cash | $3.0BFY 2025 | $5.2BFY 2025 |
| Last 12 months | ||
| Revenue | $10.3Bto 30 September 2026 | $64.4Bto 30 June 2026 |
| Net income | $348.0Mto 30 September 2026 | $6.3Bto 30 June 2026 |
| Free cash flow | $2.3Bto 30 September 2026 | $18.2Bto 30 June 2026 |
| Operating cash flow | $2.2Bto 30 September 2026 | $19.5Bto 30 June 2026 |
| Total debt | $7.8Bto 30 September 2026 | $70.8Bto 30 June 2026 |
| Cash | $1.3Bto 30 September 2026 | $6.6Bto 30 June 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.